Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: Results from a phase 1/2 trial

Ophthalmology

Volumn 119, Issue 7, 2012, Pages 1328-1335

  Liew, Shiao Hui ^a   Nichols, Kelly K ^b   Klamerus, Karen J ^a   Li, Jim Z ^a   Zhang, Min ^a   Foulks, Gary N ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; TOFACITINIB;

ADULT; APPLICATION SITE PAIN; ARTICLE; BLURRED VISION; BURNING SENSATION; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EPIPHORA; EYE DISCOMFORT; EYE PAIN; FEMALE; HUMAN; INSTILLATION SITE IRRITATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; STAINING; TEAR FILM;

CYCLOSPORINE; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; FEMALE; HUMANS; JANUS KINASE 3; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PYRIMIDINES; PYRROLES; QUESTIONNAIRES; TEARS; TREATMENT OUTCOME;

EID: 84863304245     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.01.028     Document Type: Article

References (20)

1. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf 5 2007 179 193
2. J.L. Gayton Etiology, prevalence, and treatment of dry eye disease Clin Ophthalmol 3 2009 405 412
3. N.J. Friedman Impact of dry eye disease and treatment on quality of life Curr Opin Ophthalmol 21 2010 310 316
4. P. Mertzanis, L. Abetz, K. Rajagopalan The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample Invest Ophthalmol Vis Sci 46 2005 46 50
5. S.C. Pflugfelder Prevalence, burden, and pharmacoeconomics of dry eye disease Am J Manag Care 14 suppl 2008 S102 S106
6. R.M. Schiffman, J.G. Walt, G. Jacobsen Utility assessment among patients with dry eye disease Ophthalmology 110 2003 1412 1419
7. D.A. Schaumberg, D.A. Sullivan, J.E. Buring, M.R. Dana Prevalence of dry eye syndrome among US women Am J Ophthalmol 136 2003 318 326
8. K. Ghoreschi, A. Laurence, J.J. O'Shea Janus kinases in immune cell signaling Immunol Rev 228 2009 273 287
9. D.M. Meyer, M.I. Jesson, X. Li Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis J Inflamm 7 2010 41
10. K. Ghoreschi, M.I. Jesson, X. Li Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550) J Immunol 186 2011 4234 4243
11. R. Fleischmann, M. Cutolo, M.C. Genovese Phase IIB dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum 64 2012 617 629
12. J.M. Kremer, S. Cohen, B.E. Wilkinson A Phase IIB dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone Arthritis Rheum 64 2012 970 981
13. M.G. Boy, C. Wang, B.E. Wilkinson Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis J Invest Dermatol 129 2009 2299 2302
14. S. Busque, J. Leventhal, D.C. Brennan Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients Am J Transplant 9 2009 1936 1945
15. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf 5 2007 75 92
16. M.A. Lemp Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes CLAO J 21 1995 221 232
17. M.E. Johnson, P.J. Murphy Measurement of ocular surface irritation on a linear interval scale with the Ocular Comfort Index Invest Ophthalmol Vis Sci 48 2007 4451 4458
18. R.P. Feenstra, S.C. Tseng Comparison of fluorescein and rose bengal staining Ophthalmology 99 1992 605 617
19. D.R. Korb, J.P. Herman, V.M. Finnemore An evaluation of the efficacy of fluorescein, rose bengal, lissamine green, and a new dye mixture for ocular surface staining Eye Contact Lens 34 2008 61 64
20. L.M. Machado, R.S. Castro, B.M. Fontes Staining patterns in dry eye syndrome: rose bengal versus lissamine green Cornea 28 2009 732 734